283 related articles for article (PubMed ID: 32512849)
1. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32512849
[TBL] [Abstract][Full Text] [Related]
2. Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell lines.
Juengel E; Euler S; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Nelson K; Bechstein WO; Blaheta RA
Phytomedicine; 2017 Apr; 27():1-7. PubMed ID: 28314474
[TBL] [Abstract][Full Text] [Related]
3. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759798
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.
Juengel E; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Tsaur I; Nelson K; Bechstein WO; Haferkamp A; Blaheta RA
Oncotarget; 2016 Dec; 7(51):85208-85219. PubMed ID: 27863441
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
Islam SS; Mokhtari RB; Akbari P; Hatina J; Yeger H; Farhat WA
Target Oncol; 2016 Apr; 11(2):209-27. PubMed ID: 26453055
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.
Rutz J; Thaler S; Maxeiner S; Chun FK; Blaheta RA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218199
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
9. Chronic Sulforaphane Application Does Not Induce Resistance in Renal Cell Carcinoma Cells.
Rutz J; Juengel E; Euler S; Maxeiner S; Justin S; Roos F; Chun FK; Blaheta RA
Anticancer Res; 2018 Nov; 38(11):6201-6207. PubMed ID: 30396938
[TBL] [Abstract][Full Text] [Related]
10. Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention.
Wang L; Liu D; Ahmed T; Chung FL; Conaway C; Chiao JW
Int J Oncol; 2004 Jan; 24(1):187-92. PubMed ID: 14654956
[TBL] [Abstract][Full Text] [Related]
11. Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro.
Xie H; Rutz J; Maxeiner S; Grein T; Thomas A; Juengel E; Chun FK; Cinatl J; Haferkamp A; Tsaur I; Blaheta RA
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230603
[TBL] [Abstract][Full Text] [Related]
12. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
[TBL] [Abstract][Full Text] [Related]
13. Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation.
Shawky NM; Segar L
Pharmacol Res; 2017 May; 119():251-264. PubMed ID: 28212891
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
15. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
16. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
17. Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Rutz J; Maxeiner S; Grein T; Sonnenburg M; Khadir SE; Makhatelashvili N; Mann J; Xie H; Cinatl J; Thomas A; Chun FK; Haferkamp A; Blaheta RA; Tsaur I
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232303
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
[TBL] [Abstract][Full Text] [Related]
20. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
